03 April 2024
03 April 2024
The regulatory milestone is based on the outcomes of the TROPION-Breast01 Phase III clinical trial.
Genmab partakes in the flurry of financial activity being seen with the promising cancer therapeutic modality of antibody drug conjugates.
Ipsen signed a licensing agreement to develop and commercialise Sutro Biopharma’s ADC STRO-003 intended as a treatment for solid tumours.
Jynneos contributed $725m in sales to Bavarian Nordic in 2023, being a huge driver in revenues for the company.
MASH, previously known as nonalcoholic steatohepatitis (NASH), is a disease characterised by liver inflammation and damage caused by the accumulation of fat.
So far, Lenmeldy has only generated $12.7m in product sales across Europe, meaning just a handful of children with the disease received the treatment.
The approval is based on the results from the open-label, randomised Phase III COMMANDS study.
While the use of generative AI to optimise the practitioner-to-patient relationship grows, ethical questions over bias thwart pharma’s reliance on the tech.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
